首页> 美国卫生研究院文献>Gland Surgery >Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population

【2h】

Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population

机译：BRCA1 / 2突变载体和非载体在中国人口中患有乳腺癌的非载体患者是安全的

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Gland Surgery
作者
Xin Huang; Xiu-Yu Cai; Jia-Qi Liu; Wen-Wen Hao; Yi-Dong Zhou; Xiang Wang; Ying Xu; Chang Chen; Yan Lin; Chang-Jun Wang; Yu Song; Qiang Sun;
展开▼
作者单位

展开▼
年(卷),期 2020(9),3
年度 2020
页码 -1
总页数 13
原文格式 PDF
正文语种
中图分类
关键词
Breast-conserving therapy (BCT); mastectomy; BRCA1/2 mutation; breast cancer; prognosis;

相似文献

外文文献
中文文献
专利

1. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients [J] . Alexandra J. van den Broek, Marjanka K. Schmidt, Laura J. van t Veer, Annals of Surgery . 2019,第2期

机译：哺乳治疗与BRCA1 / 2突变载体乳房切除术的预后影响与连续系列乳腺癌患者的非载体相比
2. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. [J] . Lee E, Ma H, McKean-Cowdin R, Cancer epidemiology, biomarkers and prevention: A publication of the American Association for Cancer Research . 2008,第11期

机译：生殖因素和口服避孕药对BRCA1 / 2突变携带者和非携带者的乳腺癌风险的影响：一项基于人群的研究结果。
3. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations (see comments) [J] . Turner BC, Harrold E, Matloff E, Journal of Clinical Oncology . 1999,第10期

机译：肿块切除和放射治疗后局部复发乳腺癌患者的BRCA1 / BRCA2种系突变：对BRCA1 / BRCA2突变患者的保乳管理的意义（参见评论）
4. Deleterious mutation analysis of BRCA1 based on　clinicopathologic evidence in Chinese familial and sporadic Breast cancer by whole sequencing [C] . Rensheng Lai, Changle Zhu, Lin Xie, International Forum on Progress on Post-Genome Technologies(5'IFPT); 20070910-11; Suzhou(CN) . 2007

机译：基于临床病理证据的中国家族性和散发性乳腺癌BRCA1有害突变全序列分析
5. Segregation analyses in Ashkenazi Jewish families: Evidence of an additional breast cancer susceptibility gene, and evaluation of cancer risks in BRCA1/2 mutation carriers. [D] . Kaufman, David J. 2002

机译：阿什肯纳兹犹太人家庭的隔离分析：另一个乳腺癌易感基因的证据，以及BRCA1 / 2突变携带者的癌症风险评估。
6. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer [O] . Kerryn W. Reding, Jonine L. Bernstein, Bryan M. Langholz, -1

机译：BRCA1 / BRCA2突变携带者在基于群体的对侧乳腺癌风险研究中的乳腺癌辅助全身治疗
7. Effect of Reproductive Factors and Oral Contraceptives on Breast Cancer Risk in BRCA1/2 Mutation Carriers and Noncarriers: Results from a Population-Based Study [O] . Eunjung Lee, Huiyan Ma, Roberta McKean-Cowdin, 2008

机译：生殖因子和口服避孕药对BRCA1 / 2突变载体和非载体乳腺癌风险的影响：基于人群的研究结果

Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population

著录项

相似文献

相关主题

期刊订阅